Milan Scheidegger received his MD degree at the University of Zurich and completed his PhD in neuroscience at the Institute for Biomedical Engineering (University and ETH Zurich), where he was trained in multimodal, molecular and pharmacological imaging (fMRI, MRS, PET, ASL). As a resident physician at the Department of Psychiatry, Psychotherapy, and Psychosomatics (University Hospital of Psychiatry Zurich) he is currently investigating the functional interplay between perfusion, neurometabolism, synaptic plasticity and brain function underlying the regulation of mood and cognition and its modulation by therapeutic interventions (e.g. ketamine, psilocybin). In addition to empirical research, he also obtained a MA degree in History and Philosophy of Knowledge at the ETH Zurich (MA ETH HPK). His main research interests include biosemiotics, philosophy of mind, epistemology of psychiatry and the neurophenomenology of altered states of consciousness including mindfulness and psychedelics.
On his ethnobotanical expeditions to South America (Mexico, Colombia, Brazil) he discovered the shamanic and therapeutic use of psychoactive medicines. His current research aims at providing insight into the neurobiology of consciousness and the potential of psychedelics such as ketamine, psilocybin, ayahuasca, and 5-MeO-DMT for psychotherapeutic transformation and personal development. Together with Prof. Franz Vollenweider and Zen teacher Vanja Palmers, he recently conducted a psilocybin neuroimaging study with long-term meditators in a meditation retreat setting to explore the potential of psilocybin to facilitate mystical experiences, psychospiritual well-being and a deeper understanding of the neurobiology of expanded states of self.
He is current member of the Swiss Society for Psycholytic Therapy (SÄPT) and former scholar of the Swiss Study Foundation and received the Young Investigators Award from the Swiss Society of Biological Psychiatry (2013).
Portrait by Swiss Study Foundation:
Groove und (Magnet-)Resonanz (2011)